CML (Chronic Myeloid Leukemia) is a form of cancer that can affect the production and function of red blood cells. While CML itself does not directly cause hemolytic anemia, the treatments used to manage CML can have an indirect effect on the development of this condition.
How CML Treatment Can Lead to Hemolytic Anemia
Hemolytic anemia is a condition where red blood cells are destroyed faster than they can be produced. This can be caused by a number of different factors, including certain medications and treatments.
CML treatment often involves medications called tyrosine kinase inhibitors (TKIs). These medications work by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. While these drugs can be effective in controlling CML, they can also cause a decrease in the production of red blood cells, leading to a form of anemia known as TKI-associated anemia.
TKI-associated anemia is a type of hemolytic anemia in which red blood cells are destroyed prematurely. This can cause a variety of symptoms, including fatigue, shortness of breath, pale skin, and easy bruising or bleeding.
Managing Hemolytic Anemia Caused by CML Treatment
If you have been diagnosed with CML and are experiencing symptoms of anemia, it is important to talk to your doctor about managing your condition. Your doctor may recommend lifestyle changes, such as increasing your intake of iron-rich foods, or they may suggest taking medications to help manage your anemia.
It is also important to talk to your doctor about any potential side effects of your CML treatment. Your doctor may be able to switch you to a different medication or adjust your dosage to help reduce the risk of developing TKI-associated anemia.
In some cases, your doctor may recommend a blood transfusion to help you manage your anemia. Blood transfusions are usually only necessary in severe cases, and your doctor will discuss the risks and benefits of this treatment option with you.